Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates

Core Insights - Axsome Therapeutics Inc. (NASDAQ:AXSM) is recognized as a promising mid-cap stock by leading investors, with H.C. Wainwright raising its price target from $200 to $260 while maintaining a Buy rating [1] - The company reported interim unaudited financial results for Q4 2025, projecting total product revenue of approximately $196 million [1] Revenue Projections - Axsome anticipates overall product revenue of around $638.5 million for fiscal year 2025, representing a 66% increase compared to fiscal year 2024, surpassing H.C. Wainwright's estimate of $628.3 million [2] - The primary product, AUVELITY, is expected to generate net sales of about $155.1 million in Q4 and $507.1 million for the full year 2025, significantly exceeding the firm's annual sales estimate of $397 million [2] Performance of Other Products - Other products, such as SUNOSI, are also projected to perform well, with expected revenues of $36.7 million in Q4 and $124.8 million for the entire year [3] - Axsome Therapeutics focuses on developing novel therapies for central nervous system (CNS) disorders in the US [3]